Amicor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amicor

Property Description
Active ingredient Atorvastatin (as calcium trihydrate)
Form Oral tablet (and oral suspension)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Reduction of elevated blood cholesterol (LDL-C)
Origin Synthetic compound

Defining Amicor: Type and Active Ingredient

Amicor is a specific prescription-only medicine whose active component is the synthetic compound, Atorvastatin. It is classified as an HMG-CoA reductase inhibitor, a group commonly known as statins, which are central lipid-modifying agents. The use of Atorvastatin is utilized for its efficacy in regulating blood lipid levels.

While Atorvastatin is also available under the generic name, Amicor is presented primarily as an oral tablet and is consistently positioned for use in adults and certain pediatric patients needing management of high cholesterol.

Composition and Pharmaceutical Form

Amicor is manufactured predominantly as an oral tablet for oral administration, presenting as a stable, convenient single-ingredient product. The therapeutically active substance is Atorvastatin, often incorporated in its stable salt form, Atorvastatin calcium trihydrate.

The tablet structure utilizes the active agent alongside necessary excipients—such as Calcium Carbonate and Lactose Monohydrate—to ensure the solid dosage form is stable and releases the Atorvastatin predictably into the digestive system. This composition is designed to provide consistent, long-term delivery of the synthetic compound.

General Purpose of Atorvastatin Therapy

The primary general purpose of therapy with Amicor is to substantially reduce the concentration of circulating Low-Density Lipoprotein cholesterol (LDL-C), often referred to as "bad cholesterol," in the blood. The drug achieves its effect by inhibiting a specific enzyme in the liver, which leads to a reduction in the body's internal cholesterol production.

This action addresses a major, modifiable risk factor for vascular complications. The overall benefit of this oral drug is its contribution to the primary prevention of serious cardiovascular events.

What side effects are possible with Amicor?

Possible Side Effects and Safety Information

The safety profile for Amicor (Atorvastatin), a member of the statin class, is organized in regulatory documents by the frequency of reported adverse reactions and the system or organ affected. The most frequently reported events are generally classified as Common (ge 1/100 to < 1/10) and often involve general symptoms, musculoskeletal pain, or gastrointestinal discomfort.


Official Adverse Reaction Classifications

Side effects are grouped into System-Organ Classes (SOCs). Common events include Nasopharyngitis and laboratory changes such as abnormal liver function test and increased blood creatine kinase. Other common SOCs affected are Gastrointestinal disorders (e.g., Constipation, Flatulence) and Musculoskeletal and connective tissue disorders (e.g., Myalgia, Arthralgia).

Frequency Classification Example Side Effects (Regulatory Documents)
Common Nasopharyngitis, Headache, Myalgia, Diarrhea, Hyperglycaemia
Uncommon Insomnia, Vomiting, Hepatitis, Rash
Rare / Very Rare Rhabdomyolysis, Hepatic Failure, Anaphylaxis

Serious Safety Considerations and Regulatory Restrictions

Official labeling highlights Rare but critical events, notably Rhabdomyolysis, a severe muscle disorder that can lead to acute renal failure, and Hepatic Failure. Specific safety constraints apply to the use of Atorvastatin. The medication is contraindicated in patients with active liver disease or persistent, unexplained elevations of liver enzymes, as well as during pregnancy and lactation. Furthermore, official documents note that the risk of certain musculoskeletal events may increase with dose escalation and that the risk of new-onset diabetes mellitus is associated with long-term exposure, classified as a Common safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents regarding Amicor (Atorvastatin) overdosage emphasize the management of its known severe toxicities rather than a specific overdose symptom cluster. No specific antidote or treatment is currently known for Atorvastatin overdosage, and due to the drug's high protein binding, hemodialysis is not expected to significantly enhance clearance from the body. Management focuses strictly on the use of symptomatic and supportive measures instituted as required by clinical status.


Documented Risks and Emergency Action

The most critical documented risks of severe overexposure include rhabdomyolysis, a serious muscle condition, and the potential for acute renal failure secondary to myoglobinuria. Fatal and non-fatal hepatic failure are also listed as rare post-marketing outcomes. Renal impairment is noted as a predisposing factor for rhabdomyolysis.

Patients must promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever, as these are signs requiring urgent medical evaluation. The medication must be promptly discontinued if rhabdomyolysis or serious hepatic injury is suspected or confirmed by laboratory findings such as markedly elevated creatine kinase (CK) levels or persistent transaminase elevations. Hospital monitoring and observation are required in situations of acute toxicity.

Therapeutic Uses of Amicor

What Amicor treats: main uses and benefits

Amicor (Atorvastatin) is commonly used to provide long-term support for circulatory health by addressing the factors contributing to cardiovascular risk. Its therapeutic domain is relevant for managing internal, asymptomatic systemic imbalances, rather than providing relief for immediate physical discomfort. This medication is applied in addressing conditions like dyslipidemia (abnormal blood fat levels), focusing on lowering Low-Density Lipoprotein Cholesterol (LDL-C) and managing elevated triglycerides.

It is also commonly used for Primary Prevention of major vascular events, Secondary Prevention following an established heart attack or stroke, and managing specific high-risk populations, including pediatric patients (aged 10 and older) with Familial Hypercholesterolemia (FH). The treatment contributes to easing the physiological strain that may be linked to plaque formation.

“This action may help reduce the likelihood of certain future events and may assist with reducing the likelihood of certain invasive procedures.”

Quick Fact: Relevant for Asymptomatic Systemic Imbalance

Regulatory References

  1. Official FDA Prescribing Information via DailyMed

Eligibility and Restrictions for Use

Amicor (Atorvastatin) eligibility is strictly defined by regulatory bodies based on age, reproductive status, and specific pre-existing health conditions. Use is permitted only for populations where safety and efficacy have been officially established.

Absolute Contraindications (Must Not Use)

Amicor is contraindicated and must not be used in the following populations:

  • Patients with active liver disease, including unexplained, persistent elevations of serum transaminases exceeding three times the upper limit of normal.
  • Women who are pregnant or may become pregnant, due to the potential for fetal harm.
  • Women who are breastfeeding.
  • Patients with known hypersensitivity to atorvastatin or any of the product's components.
  • Patients receiving concomitant treatment with the Hepatitis C antivirals glecaprevir/pibrentasvir.

Eligibility and Restrictions

Population Group Regulatory Eligibility Status
Adults Approved for general use in cholesterol management.
Children (≥ 10 years) Approved only for those with Heterozygous or Homozygous Familial Hypercholesterolemia.
Children (< 10 years) Safety and efficacy have not been established; not indicated.
Age 65 years or greater Classified as an official risk factor for myopathy; requires caution.
Renal Impairment No dose adjustment required; is a noted risk factor for myopathy and rhabdomyolysis.

Eligibility is also affected by a history of uncontrolled hypothyroidism or substantial alcohol consumption, which are noted as risk factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amicor (aminocaproic acid) is an antifibrinolytic agent, and its potential for drug interactions is primarily based on this mechanism of action. The main concern is the concurrent use of medicines that also promote or enhance blood clotting, which may lead to an additive prothrombotic effect and increase the risk of developing blood clots (thrombosis).

Interacting Medicinal Product Categories

Category Interaction Mechanism/Constraint
Clotting Factor Concentrates Pharmacodynamic interaction: Increased risk of thrombosis
Thrombolytic Agents Pharmacodynamic antagonism: Decreased therapeutic efficacy

The official drug labeling specifically notes that Amicor should NOT be administered simultaneously with Factor IX Complex concentrates or Anti-Inhibitor Coagulant Concentrates. This is a restriction based on the risk of an additive effect that could enhance the formation of blood clots.

Conversely, agents that break down clots, such as thrombolytic drugs (e.g., streptokinase, urokinase), may have their therapeutic effect diminished by Amicor's fibrinolysis-inhibiting action. This antagonistic effect represents another clinically relevant interaction. Patients are advised to inform their healthcare providers of all concurrent medications, including prescription and non-prescription products, to safely manage these potential interactions.

Mechanism of Action

Competitive Inhibition of Hepatic Cholesterol Synthesis

Amicor (Atorvastatin) functions as a competitive inhibitor of the enzyme HMG-CoA reductase, which controls the rate-limiting step in the mevalonate pathway—the primary route for the body's endogenous cholesterol synthesis within liver cells. By blocking this molecular step, the drug suppresses the production of new cholesterol inside the hepatocyte.

Enhanced Receptor-Mediated LDL Clearance

The resulting intracellular cholesterol depletion triggers a compensatory feedback loop, causing the liver to upregulate the expression of Low-Density Lipoprotein (LDL) receptors on its surface. This increase in receptor density accelerates the catabolism (removal) of circulating LDL-C particles from the bloodstream, leading to reduced plasma lipid concentrations.

Pleiotropic Effects on the Vascular System

Beyond its effect on lipid synthesis and clearance, the mechanism also provides cholesterol-independent (pleiotropic) effects on the vascular system. These actions involve the modulation of endothelial function and the attenuation of local vascular inflammation, which contributes to the drug's overall physiological profile.

Dosage and Administration Information

How to Use Amicor (Atorvastatin)

Amicor is prescribed for oral administration and is available as film-coated tablets in strengths of 10 mg, 20 mg, 40 mg, and 80 mg, as well as an oral suspension.


Official Dosing and Frequency

Therapy with Amicor is typically long-term (chronic), requiring daily administration. The dosage is individualized by a healthcare provider, and adjustments are typically made at intervals of four weeks or more.

Regimen Starting Dose Maximum Dose
Adults (Standard) 10 mg or 20 mg once daily 80 mg once daily
Pediatrics (HeFH, 10-17 years) 10 mg once daily 20 mg once daily

Key Administration Instructions

Amicor should be taken once daily and may be administered at any time of the day.

  • With Meals: The tablets can be taken with or without food. However, the oral suspension should be taken on an empty stomach (separated from food).
  • Tablet Handling: The film-coated tablets must be swallowed whole and should not be crushed, dissolved, or chewed.
  • Renal Impairment: No dose adjustment is required for patients with kidney impairment.
  • Missed Dose: If a daily dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time; a double dose should not be taken.

Recent Clinical Evidence

Research evidence / Overview of studies for Amicor

The clinical evaluation of Amicor (Atorvastatin) was studied for its effect on blood lipid levels and was observed in large-scale studies examining cardiovascular outcomes. The evidence comes primarily from randomized controlled trials (RCTs), which compare outcomes in a group receiving the medicine to a control group, alongside comprehensive systematic reviews.


Evidence for Primary Prevention of Cardiovascular Events

Research has explored the use of Atorvastatin in adults who are at high risk for heart attack or stroke but have no existing history of cardiovascular disease. These large-scale RCTs monitored hard endpoints such as all-cause mortality, non-fatal myocardial infarction (MI), and stroke over intermediate to long-term follow-up.

The research describes patterns related to Major Adverse Cardiovascular Events (MACE) that were observed in some of the studies. Researchers have noted that the reported changes in MACE was associated with the measured shifts in Low-Density Lipoprotein Cholesterol (LDL-C) levels. However, the research provides limited information regarding the initiation of therapy specifically for adults aged 76 years and older.


Evidence for Secondary Prevention of Cardiovascular Events

The role of Atorvastatin in patients with established disease was evaluated in a substantial number of long-term RCTs. These studies examined the recurrence of serious events and the need for revascularization procedures. The research consistently explored measurements related to the incidence of MACE and stroke across a wide range of patients with established disease. Trials frequently described a dose-related pattern in the outcomes monitored, with more intensive regimens (higher doses) observed to have different shifts in lipid biomarkers and associated clinical endpoints.


Evidence in Special Populations

Evidence for Pediatric Patients (Ages 10+) with Familial Hypercholesterolemia

Atorvastatin was evaluated in children and adolescents, typically aged 10 to 17 years, diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH). Research in this population examined surrogate endpoints, specifically the change in LDL-C and Total Cholesterol levels. The studies focused on monitoring lipid biomarker levels during the short-term follow-up period. The sample sizes were modest and follow-up durations were limited, meaning certainty remains low for long-term outcomes compared to the adult data.


What is Still Uncertain About the Research for Amicor

Evidence is limited or unavailable for specific, rare metabolic conditions known as Fredrickson Types I and V dyslipidemias. Also, for primary prevention in older adults (age 76+), data are still emerging regarding the appropriate time to initiate therapy. Comparative evidence is lacking for some endpoints, and long-term effects beyond the five-year mark are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Amicor (FAQ)

Q: How quickly should I feel a difference after starting Amicor?

A: Amicor is absorbed relatively quickly, with the drug reaching its highest measurable level in the blood relatively quickly. However, the maximum observed effect on lipid levels is typically reached within two to four weeks after starting the medicine or adjusting the dosage.

Q: Is Amicor a blood pressure medicine or for cholesterol?

A: Amicor is classified as a statin, a type of medicine used primarily to lower high cholesterol and triglyceride levels in the blood. While it may contribute to reducing cardiovascular risk, its main purpose, based on official labeling, is lipid management, not the primary treatment of high blood pressure.

Q: Can you take Amicor on an empty stomach?

A: The official administration instructions confirm that Amicor tablets can be taken either with or without food. However, if the less common oral suspension form of the medicine is prescribed, that formulation is typically instructed to be taken on an empty stomach.

Q: Is it true that Amicor can cause muscle pain?

A: Yes, regulatory documents list muscle pain (Myalgia) as a common side effect of this class of medicine. The official product information suggests patients discuss any unexplained muscle tenderness, pain, or weakness with their healthcare provider, as these symptoms can relate to a rare but serious adverse event.

Q: Is Amicor used for preventing heart attacks, or just for treating existing conditions?

A: Studies and official information indicate that Amicor is used for both. It is prescribed for primary prevention (reducing the risk of a first heart attack or stroke in high-risk patients) and secondary prevention (reducing the risk of recurrence in patients with established heart disease).

Q: How long until Amicor reaches its full effect in the body?

A: Maximum cholesterol-lowering effects (lipid reduction) are typically reached within two to four weeks after starting the medicine. This timeline is why dosage evaluations are typically made by a healthcare professional at intervals of four weeks or more.

Q: Why do doctors prescribe Amicor for people who don't feel sick?

A: Amicor is often prescribed as a preventative measure, a concept known as primary prevention. It targets a major, modifiable risk factor (high LDL cholesterol) to reduce the future likelihood of serious events like a heart attack or stroke, even if the patient is currently asymptomatic.

Q: How long does Amicor stay in your system after you stop taking it?

A: The active substance, Atorvastatin, has a mean plasma half-life of about 14 hours. However, the overall cholesterol-reducing activity in the blood, which includes its active metabolites, lasts longer—typically about 20 to 30 hours.

Q: Are there any specific lifestyle changes I should make while taking Amicor?

A: Official information indicates that Amicor is intended to be used as an adjunct to diet. This indicates that the medicine is meant to be used alongside appropriate dietary changes and a regular exercise regimen to support overall lipid management.

Q: Does Amicor have a generic version available?

A: Yes, the active ingredient in Amicor is Atorvastatin, which is widely available and prescribed under its generic name, in addition to being available under various brand names.

Q: How is the effectiveness of Amicor measured by doctors?

A: The effectiveness of Amicor is primarily measured through blood tests that check lipid levels. Doctors evaluate the drug's success by monitoring the reduction in elevated levels of Total Cholesterol (Total-C) and Low-Density Lipoprotein Cholesterol (LDL-C).

Q: What happens if you suddenly stop taking Amicor?

A: Official information emphasizes the importance of consulting with a healthcare provider before making any decision to stop taking the medication. Abruptly discontinuing the drug may lead to an increase in cholesterol levels, which could reverse the preventative benefits of the treatment.

Q: Is it normal to feel a little dizzy when first starting Amicor?

A: Regulatory documents list dizziness as a potential adverse reaction. If dizziness or any other new symptoms occur when starting Amicor, consulting with a healthcare provider is appropriate for evaluation.

Q: What kind of evidence or research backs up the use of Amicor?

A: The use of Amicor is supported by extensive clinical evidence. This includes large-scale randomized controlled trials (RCTs) that have demonstrated the drug's effectiveness in both lowering cholesterol levels and reducing the risk of major cardiovascular events.

Q: Can Amicor affect blood sugar levels in people without diabetes?

A: Official safety data has noted a small increased risk of increased blood sugar levels (hyperglycaemia) and new-onset diabetes associated with the use of statins. This is classified as a common safety pattern.

Q: Do other heart medications commonly interact with Amicor?

A: Yes, Amicor can interact with other medicines, including certain heart medications like digoxin and drugs metabolized by the CYP3A4 enzyme system. For safe use, it is important for a healthcare provider to review all concurrent medications to manage any potential interactions.

Q: Is it a problem if I occasionally drink alcohol while on Amicor?

A: Official prescribing information advises caution regarding alcohol consumption. The medicine is contraindicated in patients with active liver disease, and those who consume substantial quantities of alcohol may face an increased risk of liver-related side effects.

Q: Why do some people need to take Amicor every day?

A: Amicor is typically prescribed for daily use because it is eliminated from the body relatively quickly. Taking it every day ensures the continuous suppression of the enzyme responsible for cholesterol production, which is necessary to maintain the therapeutic effects on lipid levels.

Q: Do you need regular blood tests while taking Amicor?

A: Official guidelines recommend that liver enzyme tests be performed before starting Amicor therapy. Testing should also be done as clinically indicated thereafter, especially if a patient experiences symptoms that might suggest liver injury.

Q: What kind of studies have been done on Amicor's long-term safety?

A: The safety and efficacy of Amicor have been assessed in long-term randomized controlled trials (RCTs), with follow-up periods extending up to five years in certain studies. These trials were primarily focused on evaluating cardiovascular outcomes in adults.

Q: Can Amicor cause stomach upset or digestive issues?

A: Yes, official safety documents report gastrointestinal disorders as common side effects of Amicor. These can include issues such as diarrhea and flatulence.

Q: Why are people told to take Amicor at a specific time of day?

A: Due to its long-lasting activity in the body, Amicor can be administered at any time of the day without affecting its effectiveness. However, establishing a consistent daily routine often helps ensure the medicine is taken reliably every 24 hours.

Q: What are the typical warnings given to new users of Amicor?

A: New users are typically informed about several potential issues. These include being aware of the risk of muscle pain (myopathy), monitoring for signs of liver injury, and understanding the potential for new-onset diabetes mellitus over long-term exposure.

Q: Can people who have had a stroke take Amicor?

A: Yes, Amicor is indicated to reduce the risk of stroke in adult patients, particularly those who have existing coronary heart disease or who present with multiple other risk factors.

Q: Are skin rashes a reported side effect of Amicor?

A: Yes, official regulatory documents list rash as an uncommon side effect. In very rare cases, more severe skin reactions have also been reported with statin use.

Q: Does taking Amicor require a change in diet?

A: Yes, the medication is officially indicated as an adjunct to diet. This highlights that optimal lipid-lowering results are best achieved when the medication is combined with a proper, health-conscious diet.

Q: Is Amicor widely accepted by major medical organizations?

A: The extensive clinical study data and its approval by major regulatory bodies globally (such as the FDA and EMA) indicate that the use of Amicor for lipid management is highly clinically recognized and supported.

Q: Can Amicor make existing mental health conditions worse?

A: Official side effect reports list insomnia (difficulty sleeping) as an uncommon adverse reaction. There is no common or uncommon adverse reaction listing for severe psychiatric or general mood changes in the official safety documents.

Q: Does Amicor have any known interactions with grapefruit or its juice?

A: Yes, official product information indicates an interaction exists. Patients are advised to avoid consuming large quantities of grapefruit juice, specifically more than 1.2 liters per day, as it can potentially increase the amount of the drug in the body.

How should Amicor be stored and disposed of?

How to Store and Dispose of Amicor (Atorvastatin)

Official regulatory guidelines mandate specific conditions for storing and discarding Atorvastatin, the active ingredient in Amicor, to maintain its stability and ensure safety.

Storage Requirements

The medication must be stored at room temperature, kept in its original container, and securely tightly closed. Crucially, it must be protected from excessive heat, moisture, and direct light, and should never be frozen. To prevent accidental ingestion, the product must be stored out of the reach of children, with the safety cap locked.

Disposal Instructions

Outdated or unused medicine should not be kept. For proper disposal, patients must consult a pharmacist or healthcare professional. Regulatory guidance advises against discarding the medicine in household trash or pouring it down a drain, unless explicitly instructed otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amicor found in:

A-Z Index: